Stock comparison
Generate Biomedicines
MSCI
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GENB
Generate Biomedicines
Market cap
$1.86B
Sector
Financials
MSCI
MSCI
Market cap
$42.85B
Sector
Financials
Overall winner
MSCI MSCI
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GENB | MSCI | Winner |
|---|---|---|---|
| Warren Buffett | 52D | 80A | MSCI |
| Benjamin Graham | 44D | 71B | MSCI |
| Philip Fisher | 78B | 82A | MSCI |
| Peter Lynch | 100A | 70B | GENB |
| Joel Greenblatt | 4F | 80A | MSCI |
| Charlie Munger | 77D | 87C | MSCI |
| Terry Smith | 79B | 88C | MSCI |
Side-by-side metrics
| Metric | GENB | MSCI |
|---|---|---|
| Market cap | $1.86B | $42.85B |
| P/E (TTM) | - | 31.2x |
| EV/EBIT | - | 27.5x |
| ROIC (TTM) | -89.38% | 38.53% |
| Gross margin | 100.0% | 82.86% |
| Net margin | -6.37% | 40.74% |
| Revenue CAGR 5y | 55.89% | 11.29% |
| EPS CAGR 5y | - | 15.35% |
| Debt / Equity | - | - |
| Dividend yield | 0.0% | 1.37% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GENB leads on
- EV/EBIT-vs 27.5x+131%
- P/E (TTM)-vs 31.2x+113%
- Revenue CAGR 5y55.89%vs 11.29%+80%
- Gross margin100.0%vs 82.86%+17%
MSCI leads on
- ROIC (TTM)38.53%vs -89.38%+143%
- Net margin40.74%vs -6.37%+106%
- Dividend yield1.37%vs 0.0%+100%
- Market cap$42.85Bvs $1.86B+96%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.